Clinical Trial Update: A Clinical Study to Evaluate Safety of the ExAblate 2100 UF V2 System in the Treatment of Symptomatic Uterine Fibroids [NA]

View source ↗

Summary

Completed safety study of the ExAblate 2100 UF V2 System in the treatment of symptomatic uterine fibroids. The trial was sponsored by InSightec.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Fibroids

Snippet

Sponsor: InSightec | Conditions: Uterine Fibroids, Bleeding | NA | Status: COMPLETED